 GSK PLC LSE:GSK, NYSE:GSK remained on the sell list at UBS despite the favourable Zantac ruling in the US today which it said is clearly a positive development for the defendants. But it pointed out its sell rating is not based on the Zantac litigation it assumes no liability in its valuation. 